Medtronic (MMED) reports 252.8M shares, 90% of MiniMed Group

Rhea-AI Filing Summary

Medtronic plc reports 252,813,348 shares beneficially owned of MiniMed Group, Inc. The Schedule 13G filing states Medtronic has sole voting and sole dispositive power over 252,813,348 shares, representing 90.0% of the class based on 280,819,988 shares outstanding as of April 11, 2026. The filing lists Medtronic Global Holdings S.C.A. as the record holder of those shares and is signed by Brian Sandstrom, VP, Chief Corporate and Securities Counsel.

Insights

Equity Ownership Specialist

Medtronic holds a controlling stake in MiniMed Group with sole voting and dispositive power.

Medtronic reports beneficial ownership of 252,813,348 shares, equal to 90.0% of outstanding common stock as of April 11, 2026. The shares are held of record by Medtronic Global Holdings S.C.A., an indirect wholly-owned subsidiary.

Such a concentration implies single‑party control over shareholder voting for routine and extraordinary matters; subsequent filings will disclose any changes to this position.

Corporate Governance Analyst

Schedule 13G indicates passive/beneficial ownership reporting; governance implications hinge on control actions.

The filing lists sole voting authority and dispositive power, which for governance purposes functions like control although Schedule 13G is typically used for passive investors. The record holder and corporate parent relationship is specified in the filing.

Watch for any future amendments or Schedule 13D filings if the ownership purpose changes.

Key Figures

Shares beneficially owned: 252,813,348 shares Percent of class: 90.0% Shares outstanding (as of): 280,819,988 shares +2 more

5 metrics

Shares beneficially owned 252,813,348 shares Amount reported by Medtronic in Schedule 13G

Percent of class 90.0% Percent of common stock based on outstanding shares as of April 11, 2026

Shares outstanding (as of) 280,819,988 shares Shares outstanding used to calculate percentage as of April 11, 2026

CUSIP 60365F109 MiniMed Group common stock CUSIP listed on the filing

Filer signature date 05/06/2026 Date signature by Brian Sandstrom on the Schedule 13G

Key Terms

Schedule 13G, beneficially owned, sole dispositive power, sole voting power

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: MiniMed Group, Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Item 4. (a) Amount beneficially owned: 252,813,348"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Item 4. (iii) Sole power to dispose or to direct the disposition of: 252,813,348"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power regulatory

"Item 4. (i) Sole power to vote or to direct the vote: 252,813,348"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MiniMed Group, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

60365F109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 60365F109

1

Names of Reporting Persons

Medtronic plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

IRELAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 252,813,348.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 252,813,348.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

252,813,348.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

90.0 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: Number of shares beneficially owned reported in Rows 5 and 7 consists of shares held of record by Medtronic Global Holdings S.C.A., an indirect, wholly-owned subsidiary of Medtronic plc. Percentage reported in Row 11 is based on 280,819,988 shares of common stock outstanding as of April 11, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on April 17, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MiniMed Group, Inc.
(b)	Address of issuer's principal executive offices: 18000 Devonshire Street, Northridge, CA 91325
Item 2.
(a)	Name of person filing: Medtronic plc
(b)	Address or principal business office or, if none, residence: Building Two, Parkmore Business Park West, Galway, Ireland H91 4K49
(c)	Citizenship: L2
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP Number(s): 60365F109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 252,813,348
(b)	Percent of class: 90.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 252,813,348
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 252,813,348
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Medtronic plc

Signature:	/s/ Brian Sandstrom
Name/Title:	Brian Sandstrom/VP, Chief Corporate and Securities Counsel
Date:	05/06/2026

FAQ

What stake does Medtronic (MMED) report in MiniMed Group?

Medtronic reports beneficial ownership of 252,813,348 shares, equal to 90.0% of common stock. The percentage is based on 280,819,988 shares outstanding as of April 11, 2026, per the filing.

Who holds the shares reported by Medtronic in MiniMed Group?

The shares are held of record by Medtronic Global Holdings S.C.A., an indirect wholly‑owned subsidiary of Medtronic plc. Medtronic reports sole voting and dispositive power over those shares.

Does this Schedule 13G filing signal a change in control for MiniMed Group (MMED)?

The filing documents that Medtronic has sole voting power over 90.0% of shares, which reflects de facto control. The filing itself does not state any transaction or change of control beyond the reported ownership figures.

When was the ownership percentage calculated in the MiniMed Group filing?

The percentage is calculated using 280,819,988 shares outstanding as of April 11, 2026, cited in the filing and traced to the issuer's Form 10‑Q referenced in the Schedule 13G.

Who signed the Schedule 13G for Medtronic on behalf of the filer?

The filing is signed by Brian Sandstrom, Vice President, Chief Corporate and Securities Counsel, with a signature date of May 6, 2026, as shown in the filing.